Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
Currency:  $ £
Discounted Reports
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare

Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech

Enquire | Email | Print

Click Here!!! and Get this report in a Combo Package with 20% OFF!!!
Published Date: Jan, 2014
Format: PDF
No of Pages: 74
Select pricing :
Change Currency: EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

Positive sentiments for the biotech sector have prevailed in the last two to three years, and we expect this trend to continue for the next year too. Our optimism is based on the continuity in the flow of innovative products from their pipeline, implementation of strategic decisions to improve cost efficiency, strengthen therapeutic leadership, and hedge against generic threats – which all lend stability to the business model of the company. Focus and interest in Orphan diseases remains and Alexion kept everyone guessing on the possible acquisition. BMRN, Alexion are likely candidates to be acquired in this space.

In the next five years the distinction between some mature biotech companies and large global pharma may become blurred esp. if there is consolidation within the sector. AMGN was the first amongst the peers to declare a dividend and this has raised the bar/expectations from others too. First mAb Biosimilar (Hospira’s infliximab – Inflectra) was approved in EU and the pipeline, competition intensifies despite no firm regulatory pathway is defined in US.

The detailed 72 pages report contains the detailed discussion of the key attributes of leading biotech companies’ Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron and Vertex. 

Macro Analysis
-Key Attributes of Leading Biotech Companies
-New Drug Approval in 2013-16
-Key Milestones during 2014/15
-Merger and Acquisitions
-Biosimilars in developments

In-depth Company Analysis and Reports on

1. Acorda Therapeutics – Pipeline of NDDS Drugs targeting Niche Indications
-Marketed Products - Ampyra and Qutenza
-Label expansion of Ampyra
-Pipeline beyond Ampyra

2. Alexion Pharma – Focus on Innovative Drugs for Orphan/ Ultra-rare Diseases With No Competition Visible!
-Product Pipeline – Future Potential
-Soliris in PNH and aHUS: Growth to Continue
-Soliris beyond PNH and aHUS
-Diversifying Beyond Soliris - Asfotase alfa
-Early stage programs – Cyclic Pyranopterin Monophosphate, ALXN1007, ALXN1102

3. Amgen – Late-Stage Pipeline Carries Potential to Counteract Expected Headwinds
-Late-Stage Pipeline
-Biosimilar Opportunity & Competition
-Partnership and Acquisitions
-Competitive Landscape: Anti-PCSK9 mAb – Hyperlipidemia

4. Biogen Idec – Near-Term Growth Prospects Driven by Core Business + New Product Launches
-Long-Acting Hemophilia Drugs – ELOCTATE and ALPROLIX
-Detailed data from long-lasting recombinant FVIII and FIX
-Superiority of Gazyva against Rituxan in CLL
-BIIB’s MS Franchise – Strengthening its Leadership

5. Celgene – Innovative Strategies for Long Term Gains
-Growth from marketed products and label expansion of Revlimid, ABRAXANE, POMALYST/IMNOVID, Vidaza
-Novel Early Stage Products - Sotatercept, ACE-536, CC-292, MOR202, CC-223, EPZ5676, CC-220

6. Gilead Sciences – Poised to Emerge as a Leader in HCV Treatment
-Sofosbuvir/ Ledispavir FDC
-Development Pipeline
-HIV Life cycle management
-Beyond Anti-Virals – Idelalisib, Momelotinib, Simtuzumab, GS-9973
-Technology platform – Dual-Afnity Re-Targeting (DART)

7. Regeneron – Label Expansion Sustains Eylea’s Growth Momentum + Late Stage Pipeline Potential Poised For Further Contribution
-Marketed Products – Eylea, Arcalyst, ZALTRAP
-Label expansion of Eylea in DME and BRVO indication
-Late-Stage Pipeline - Alirocumab, Sarilumab, Dupilumab
-REGN-Sano Collaboration

8. Vertex Pharma – Focus Shift to Cystic Fibrosis and Niche Indications
-Cystic Fibrosis: Success in G551D mutation to Repeat in Larger Population of del508 Mutation
-Small But Meaningful Addition in Other Mutations for KALYDECO
-PhII data from KALYDECO / VX-809
-PHIII studies for KALYDECO and VX- 809/KALYDECO in homozygous CF pts
-HCV Glory Faded Very Soon
-Beyond CF and HCV – VX-509, VX-787, VX-767
-KEY Pipeline Products: IFN-Free Combinations for HCV

Industry Tables
1. Pipeline Potential Thru 2018
2. Marketed Products’ Potential
3. Sector Selected Companies M&A Activities
4. Expected Drug Clinical Milestones

Related Reports:  


Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.


Top Go to top of the page

product id: 364881, price: INR 152260, MP Advisors

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
About Trust Online